Business

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated

articleCosmos Health Inc.January 23, 20255/company/cosmos-health-inc/news/cosmos-health-signs-expanded-exclusive-distribution-agreement-with-virax-biolabs-for-avian-influenza-virus-pcr-kits-in-saudi-arabia-the-uae-qatar-and-kuwait
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

About this update from Cosmos Health Inc.

[{"type":"text","content":"CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) (\"Virax\") to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across all remaining Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the United Arab Emirates (UAE), Qatar, and Kuwait.The previous exclusive distribution agreement, announced on January 13, 2025, was limited to Oman and Bahrain. Under the new agreement, Cosmos Health is now authorized to import, sell, and distribute ViraxClear-branded kits throughout all GCC countries.Greg Siokas, CEO of Cosmos Health, stated: \"We are delighted to deepen our collaboration with Virax and contribute to effective public health responses throughout all GCC countries.\"About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the teleheal...

More updates from Cosmos Health Inc.